Intravenous immunoglobulin treatment in peripheral nerve disorders-indications, mechanisms of action and side-effects

Current Opinion in Neurology

Volumn 13, Issue 5, 2000, Pages 575-582

  Hahn, Angelika F ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; DRUG MECHANISM; GUILLAIN BARRE SYNDROME; HUMAN; HYPERSENSITIVITY; IMMUNOTHERAPY; KIDNEY DISEASE; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; SKIN MANIFESTATION;

AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PARANEOPLASTIC SYNDROMES; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RISK FACTORS;

EID: 0033782797     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200010000-00012     Document Type: Article

References (84)

1. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines
2. Intravenous immunoglobulin treatment of neurological autoimmune disease
3. Manipulating the immune system with immune globulin
4. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors
5. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome
6. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome
7. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia
8. University consortium expert panel, 1995. Recommendations for off-label use of intravenously administered immunoglobulin preparations
9. Complications of intravenous immune globulin treatment in neurologic disease
10. Complications of intravenous gammaglobulin in neuromuscular and other diseases
11. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase
12. Effect of high-dose intravenous immunoglobulin therapy on blood rheology
13. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases
14. High-dose intravenous immunoglobulin treatment and cerebral vasospasm: A possible mechanism of ischemic encephalopathy?
15. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: Case report and literature review of intravenous immunoglobulin-related thrombotic complications
16. Hyperviscosity in HIV infected children: A potential hazard during intravenous immunoglobulin therapy
17. High-dose intravenous immune globulin and acute renal failure
18. Acute renal failure resulting from intravenous immunoglobulin therapy
19. Acute renal failure after large doses of intravenous immune globulin
20. Intravenous immunoglobulin induced nephropathy: A complication of IVIg therapy
21. Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease
22. Meningitis and skin reactions after intravenous immunoglobulin therapy
23. Alopecia after immunoglobulin infusion
24. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases
25. Neutropenia as a complication of intravenous immunoglobulin (IVIg) therapy in children with immune thrombocytopenic purpura: Common and non-alarming
26. Intravenous immunoglobulin infusion causing pseudohyponatremia
27. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases
28. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune disease
29. IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome
30. Intravenous immunoglobulins and transforming growth factor β
31. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments
32. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barre syndrome, myasthenia gravis and dermatomyositis
33. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy
34. Fc portion of intravenous immunoglobulins suppresses the induction of experimental allergic neuritis
35. Intravenous immunoglobulin contains specific antibodies inhibitory of activation of T cells by staphylococcal toxin super-antigens
36. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis
37. Human autoimmune neuropathies
38. Autoantibodies associated with peripheral neuropathy
39. Miller Fisher anti-GQ1b antibodies; α-latrotoxin-like effects on motor end plates
40. Fisher syndrome with tetraparesis and antibody to GQ1b: Evidence for motor nerve terminal block
41. Autoantibodies to GM1b and GaINAc-GD1a: Relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China
42. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome
43. Anti-GaINAc-GD1a antibody-associated Guillain-Barre syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance
44. Rapidly progressive, predominantly motor Guillain-Barre syndrome with anti-GaINAc-GD1a antibodies
45. Clinical presentation and outcome of Guillain-Barre and related syndromes in relation to anti-ganglioside antibodies
46. Clinicopathological study of an autopsy case with sensory-dominant polyradiculoneuropathy with antiganglioside antibodies
47. Degeneration of rabbit sensory neurons induced by passive transfer of anti-GD1b antiserum
48. The distribution of ganglioside-like moieties in peripheral nerves
49. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome
50. Pilot trial of immunoglobulin vs. plasma exchange in patients with Guillain-Barre syndrome
51. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome
52. Electrophysiological classification of Guillain-Barre syndrome: Clinical associations and outcome. Plasma exchange/sandoglobulin Guillain-Barre syndrome trial group
53. Risk factors for treatment related clinical fluctuations in Guillain-Barre syndrome
54. The use of intravenous immunoglobulin in Miller Fisher syndrome
55. Idiopathic dysautonomia treated with intravenous gammaglobulin
56. Treatment of acute pandysautonomia with intravenous immunoglobulin
57. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP)
58. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: A long-term follow-up study
59. Multifocal acquired demyelinating sensory and motor neuropathy: The Lewis-Sumner syndrome
60. Multifocal inflammatory demyelinating neuropathy. A distinct clinical entity?
61. Focal upper limb demyelinating neuorpathy
62. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy
63. Axonal perikaryal involvement in chronic inflammatory demyelinating polyneuropathy
64. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy
65. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double blind placebo controlled cross-over study
66. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study
67. Intravenous immunoglobulin (IVIg) in untreated patients with chronic inflammatory demyelinating polyradiculoneuropathy
68. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy
69. The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders
70. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease
71. Multifocal demyelinating motor neuropathy: Cranial nerve involvement and immunoglobulin therapy
72. Patterns of reactivity of human anti-GM1 antibodies with spinal cord and motor neurons
73. Mapping immunoreactive epitopes in the human peripheral nervous system using human monoclonal anti-GM1 ganglioside antibodies
74. Multifocal motor neuropathy: Response to human immune globulin
75. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study
76. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: A double blind, placebo controlled study
77. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy
78. Progression of multifocal motor neuropathy during apparently successful treatment with human immunoglobulin
79. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IGM paraproteinemia
80. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy
81. Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy
82. Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy
83. Utility of antiHu antibodies in the diagnosis of paraneoplastic sensory neuropathy
84. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies